Invasive pneumococcal disease surveillance in Canada, 2021–2022

202425 citationsJournal Articlediamond Open Access

Authors

Averil Griffith · Public Health Agency of Canada

Alyssa Golden · Public Health Agency of Canada

Brigitte Lefebvre

Allison McGeer · Mount Sinai Hospital

Gregory J. Tyrrell · Provincial Laboratory of Public Health

George G. Zhanel · University of Manitoba

Julianne V. Kus · University of Toronto

Abstract

The number of cases of IPD continued to decrease in 2021 in comparison to previous years, however, 2022 saw a return to pre-COVID-19 levels. Disease due to PCV13 serotypes 3, 4, 9V and 19F, as well as non-PCV13 serotypes 12F and 20, is increasing in prevalence. Surveillance of IPD to monitor changing serotype distribution and antimicrobial resistance is essential.

Topics & Keywords

Pneumonia and Respiratory Infections Respiratory viral infections research Pneumocystis jirovecii pneumonia detection and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Canada Communicable Disease Report

Volume 50, Issue 5, pp. 121-134

DOI: 10.14745/ccdr.v50i05a02

Field-Weighted Citation Impact: 9.86